Casey Alexandra Jarvis, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Craniotomy | 4 | 2023 | 730 | 0.910 |
Why?
|
| Patient Readmission | 5 | 2021 | 3286 | 0.860 |
Why?
|
| Patient Discharge | 3 | 2021 | 3461 | 0.580 |
Why?
|
| Glioma | 2 | 2020 | 3493 | 0.300 |
Why?
|
| Depressive Disorder | 1 | 2021 | 3714 | 0.300 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1882 | 0.280 |
Why?
|
| Brain Neoplasms | 4 | 2021 | 9071 | 0.280 |
Why?
|
| Single-Chain Antibodies | 1 | 2024 | 114 | 0.210 |
Why?
|
| Neoplasms | 3 | 2021 | 22340 | 0.210 |
Why?
|
| Postoperative Complications | 2 | 2020 | 15747 | 0.180 |
Why?
|
| Hospital Charges | 1 | 2023 | 345 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2021 | 8067 | 0.180 |
Why?
|
| Depression | 1 | 2020 | 8237 | 0.180 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2019 | 59 | 0.160 |
Why?
|
| Ultrasonic Therapy | 1 | 2021 | 216 | 0.160 |
Why?
|
| HLA-A1 Antigen | 1 | 2017 | 9 | 0.140 |
Why?
|
| Sex Factors | 2 | 2021 | 10603 | 0.130 |
Why?
|
| Consciousness Disorders | 1 | 2020 | 445 | 0.130 |
Why?
|
| Phosphotransferases | 1 | 2016 | 302 | 0.120 |
Why?
|
| Aneurysm, Ruptured | 1 | 2019 | 456 | 0.110 |
Why?
|
| Length of Stay | 3 | 2023 | 6485 | 0.110 |
Why?
|
| Drainage | 1 | 2019 | 1179 | 0.110 |
Why?
|
| Prevalence | 2 | 2021 | 15842 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2024 | 2570 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 1229 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1240 | 0.100 |
Why?
|
| Risk Factors | 5 | 2021 | 74840 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 81514 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 1365 | 0.080 |
Why?
|
| Intracranial Aneurysm | 1 | 2019 | 1272 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 2002 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 3646 | 0.070 |
Why?
|
| Aged | 7 | 2023 | 171117 | 0.070 |
Why?
|
| Middle Aged | 7 | 2023 | 223009 | 0.060 |
Why?
|
| Comorbidity | 1 | 2020 | 10563 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4528 | 0.060 |
Why?
|
| Adult | 6 | 2021 | 223044 | 0.060 |
Why?
|
| Male | 8 | 2023 | 363698 | 0.050 |
Why?
|
| Female | 8 | 2023 | 396112 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 59489 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8611 | 0.040 |
Why?
|
| Ultrasonics | 1 | 2021 | 209 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2020 | 128 | 0.040 |
Why?
|
| Humans | 12 | 2024 | 765968 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 59889 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2023 | 474 | 0.040 |
Why?
|
| Suction | 1 | 2019 | 265 | 0.040 |
Why?
|
| Adolescent | 3 | 2020 | 88835 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 462 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 413 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2023 | 1470 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 223 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2021 | 788 | 0.030 |
Why?
|
| Morbidity | 1 | 2019 | 1749 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 1510 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2016 | 558 | 0.030 |
Why?
|
| United States | 1 | 2020 | 72903 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 1543 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 17075 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 1490 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3608 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 2074 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 9649 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2832 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3421 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5343 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 10261 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13266 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 9550 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 4642 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 65188 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2016 | 4752 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2023 | 41649 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 81819 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2019 | 26346 | 0.010 |
Why?
|
| Stroke | 1 | 2020 | 9747 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 36386 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 18293 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 42500 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20659 | 0.010 |
Why?
|
| Animals | 2 | 2017 | 168764 | 0.010 |
Why?
|
| Child | 1 | 2019 | 80564 | 0.010 |
Why?
|